Related Experiment Video

Updated: Sep 14, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Targeting CDK2 and other novel cell cycle targets for breast cancer therapy

Mei-Kuang Chen1, Linjie Luo1, Nicole Massoumi1,2

  • 1Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Expert Opinion on Therapeutic Targets
|July 22, 2025
PubMed
Abstract

Insights

Targeting cyclin-dependent kinase 2 (CDK2) is a promising strategy for CDK4/6 inhibitor-resistant breast cancer. CDK2 inhibitors show efficacy alone and in combination therapies, offering new treatment avenues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) dysregulation drives cancer progression, making them key therapeutic targets.
  • CDK4/6 inhibitors (CDK4/6i) are used in breast cancer, but resistance develops.
  • CDK2 hyperactivation is a common resistance mechanism to CDK4/6i, sustaining proliferation.

Purpose of the Study:

  • To review the biological roles and regulation of CDK2.
  • To highlight advancements in CDK2 inhibitors (CDK2i) and their mechanisms.
  • To explore combination strategies involving CDK2i and other therapies.

Main Methods:

  • Literature review of CDK2 biology and inhibitors.
  • Analysis of preclinical and clinical data on CDK2i.
  • Exploration of emerging therapeutic targets like CDK7 and CDK5.

Main Results:

  • CDK2 inhibitors demonstrate significant anti-tumor activity.
  • Combinations of CDK2i with CDK4/6i, chemotherapy, or immunotherapy show enhanced efficacy.
  • CDK7 and CDK5 are identified as other relevant targets in breast cancer.

Conclusions:

  • CDK2 inhibitors represent a viable therapeutic option for CDK4/6i-resistant breast cancer.
  • Optimizing combination strategies and patient selection via biomarkers is crucial.
  • Targeting CDK2, CDK7, and CDK5 offers a multi-pronged approach for improved breast cancer treatment.
Keywords:
CDK2 inhibitorCDK4/6 inhibitorCDK5CDK7 inhibitorbreast cancertargeted therapies

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K